Larimar Therapeutics LRMR
NASDAQ LRMR
$2.73 +0.04 (+1.49%)
At close: Nov 11, 2026 · 4:00 PM EST

Larimar Therapeutics (LRMR) Preferred Stock Liabilities (2013 - 2014)

Updated

Larimar Therapeutics (LRMR) recorded Preferred Stock Liabilities of $103.8 million in Q4 2013.

Analysis

Larimar Therapeutics (LRMR) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends

  • Across earlier years, Preferred Stock Liabilities came in at $62.79 million in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Larimar Therapeutics 279.45 Mn -389.49 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 103.80 Mn
Sep 30, 2014 103.80 Mn
Jun 30, 2014 103.80 Mn
Dec 31, 2013 103.80 Mn
API Access

Larimar Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=LRMR&period=max&api_key=YOUR_API_KEY